Apnea-hypopnea index

There are 261 papers on apnea-hypopnea index in aging research: 27 trials and 181 observational studies in people, 47 reviews. The newest story, Nov 19, 2026: “Sleep apnea deaths showed different patterns by sex and age”.

Biomarker

261 papers study it61 more mention it87 findings

35 new papers in 30 daysSee all 322 papers on apnea-hypopnea index

“The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies.”
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weightSleep medicine2025doi:10.1016/j.sleep.2025.106853
  • Human trial27
  • Humans181
  • In silico4

Interventions

21

Tirzepatide

downin humans7downin reviews1

8 studies
  1. Tirzepatide decreases apnea-hypopnea index in humans (obstructive sleep apnea) (Often exceeding 40–50% reduction in many patients).

    “Incretin-based therapies (e.g., Tirzepatide) produce large and clinically meaningful reductions in Apnoea-Hypopnea Index (AHI), often exceeding 40–50% in many patients.”

    Reviewobstructive sleep apnea

    The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine

    Lung India : official organ of Indian Chest Society

  2. Tirzepatide decreases apnea-hypopnea index in humans (20.0 and 23.8 events per hour relative to placebo).

    “Tirzepatide reduced the apnea-hypopnea index by an estimated 20.0 and 23.8 events per hour relative to placebo”

    Reviewobesity and moderate-to-severe obstructive sleep apnea; trials without and during established positive airway pressure use52 weeksn = 469

    Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice

    Cardiology in review

  3. Tirzepatide decreases apnea-hypopnea index in humans (reduces AHI to 12-30 events per hour).

    “Incretin-based therapies, particularly Tirzepatide, achieve 10%-22% weight loss and reduce AHI to 12-30 events per hour”

    Review

    Anti-Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

    Chronic diseases and translational medicine

  4. Tirzepatide decreases apnea-hypopnea index in humans (reported in emerging clinical studies reviewed).

    “Emerging clinical studies have shown potential improvement in apnea-hypopnea index (AHI) and oxygenation.”

    Reviewreported in emerging clinical studies reviewed

    Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction

    Current hypertension reviews

  5. Tirzepatide decreases apnea-hypopnea index in patients with OSA and coexisting obesity.

    “Tirzepatide has demonstrated significant reductions in apnea-hypopnea index (AHI) among patients with OSA and coexisting obesity.”

    Reviewin patients with OSA and coexisting obesity

    Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea

    Current opinion in endocrinology, diabetes, and obesity

  6. Tirzepatide decreases apnea-hypopnea index in OSA patients.

    “The recent SURMOUNT-OSA study showed that tirzepatide significantly reduced the apnea hypopnea index (AHI) in OSA patients”

    Reviewin OSA patients

    Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

  7. Tirzepatide decreases apnea-hypopnea index in obese adults with moderate-to-severe OSA (55-63% AHI reduction).

    “GLP-1 receptor agonists, particularly tirzepatide, received FDA approval as the first medication for moderate-to-severe OSA in obese adults, showing a 55-63% AHI reduction.”

    Reviewin obese adults with moderate-to-severe OSA

    Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea

    International journal of molecular sciences

  8. Tirzepatide decreases apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea and obesity (SURMOUNT-OSA).

    “tirzepatide, a new GIP/GLP-1 receptor co-agonist, reduced the apnea-hypopnea index, hypoxic burden, and body weight in adults with moderate-to-severe obstructive sleep apnea and obesity”

    Reviewin adults with moderate-to-severe obstructive sleep apnea and obesity (SURMOUNT-OSA)

    Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials

    Current obesity reports

More on Tirzepatide

GLP-1 receptor agonists

downin humans2upin humans1

3 studies
  1. GLP-1 receptor agonists decrease apnea-hypopnea index in obesity-associated obstructive sleep apnea.

    “Clinically, liraglutide and tirzepatide have reduced the apnea-hypopnea index (AHI)”

    Reviewin obesity-associated obstructive sleep apnea

    GLP-1 Receptor Agonists in Obstructive Sleep Apnea: A Translational Perspective on Mechanisms and Clinical Implications

    International journal of molecular sciences

  2. GLP-1 receptor agonists improve apnea-hypopnea index in humans (pharmacologic weight loss in SCALE Sleep Apnea).

    “SCALE Sleep Apnea established proof of concept that pharmacologic weight loss can improve the primary apnea-hypopnea index (AHI) outcome”

    Reviewpharmacologic weight loss in SCALE Sleep Apnea

    Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility

    Nature and science of sleep

  3. GLP-1 receptor agonists decrease apnea-hypopnea index in humans (pooled across three randomized trials of adults with obstructive sleep apnea) (MD -16.57 events per hour, 95% CI [-27.41, -5.73], p = 0.003).

    “Pooled analysis of patients administered GLP-1 agonists or tirzepatide showed improvement in Apnea/Hypopnea Index (MD -16.57 events per hour, 95% CI [-27.41, -5.73], p = 0.003)”

    Reviewpooled across three randomized trials of adults with obstructive sleep apnea

    Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials

    European clinical respiratory journal

More on GLP-1 receptor agonists

Resistance training

no changein humans1downin humans1

2 studies
  1. Resistance training decreases apnea-hypopnea index in humans.

    “When adjusted for the baseline AHI, ANCOVA showed a significant decrease in AHI for the EG compared to the control group (F1,141=4.30; p = 0.04).”

    Human trialseven weeksn = 144

    Strength training and light physical activity reduces the apnea-hypopnea index in institutionalized older adults

    Journal of the American Medical Directors Association

  2. Resistance training decreases apnea-hypopnea index in humans (from 20.2 (SD ±1.3) at baseline to 16.7 (SD ±0.9) at 7 weeks).

    “Adjusted means in the EG group showed a decrease in AHI from 20.2 (SD ±1.3) at baseline to 16.7 (SD ±0.9) at 7 weeks.”

    Human trial7 weeks

    Strength training and light physical activity reduces the apnea-hypopnea index in institutionalized older adults

    Journal of the American Medical Directors Association

  3. Resistance training showed no clear effect on apnea-hypopnea index in humans (obstructive sleep apnea) (MD -5.88 events·h−1, -17.25 to 5.49, p = 0.16).

    “RT showed no significant change (MD -5.88 events·h−1, -17.25 to 5.49; p = 0.16).”

    Reviewobstructive sleep apnea

    Efficacy of therapies based on muscle strength training among individual with obstructive sleep apnea - a systematic review and meta-analysis

    Respiratory medicine

More on Resistance training

Continuous positive airway pressure

downin humans2

2 studies
  1. Continuous positive airway pressure is linked with lower apnea-hypopnea index in humans (obstructive sleep apnea) (3.9, IQR: 1.8-6.5 vs. 15, IQR:7.5-29.1; p < 0.001).

    “The CPAP-treated group showed a significantly lower residual Apnea-Hypopnea Index compared to the oxygen therapy group”

    Humansobstructive sleep apnean = 370

    Continuous Positive Airway Pressure Versus Nocturnal Oxygen in Obstructive Sleep Apnea: A Propensity Score Matching Study

    Advances in respiratory medicine

  2. Continuous positive airway pressure is linked with lower apnea-hypopnea index in humans (Multiple system atrophy and sleep-disordered breathing) (Normalization).

    “The introduction of CPAP had immediate benefits, including the normalization of the apnea-hypopnea index”

    HumansMultiple system atrophy and sleep-disordered breathingOne night

    Immediate Effect of Continuous Positive Airway Pressure Therapy on Sleep and Respiration in Patients with Multiple System Atrophy and Sleep-Disordered Breathing

    Movement disorders : official journal of the Movement Disorder Society

More on Continuous positive airway pressure

Supplemental oxygen therapy

downin humans1

1 study
  1. Supplemental oxygen therapy decreases apnea-hypopnea index in humans (CI = [−8.7, −0.7]).

    “The mean NREM AHI was 37.7 events/hour (SD = 20.3) at room air condition compared to 32.9 events/hour (SD = 19.7) at NOS condition (paired T-test, CI = [−8.7, −0.7], p = 0.023, ).”

    Human trialtwo nightsn = 68

    Procedural learning worsens with OSA severity in older adults and is insensitive to short exposure supplemental oxygen therapy

    Sleep medicine

  2. Supplemental oxygen therapy decreases apnea-hypopnea index in humans (participants with OSA severity >15 events/hour or below-median pharyngeal collapsibility).

    “we found a significant treatment effect on AHI among participants with OSA severity >15 events/hour or among those with below-median pharyngeal collapsibility.”

    Human trialparticipants with OSA severity >15 events/hour or below-median pharyngeal collapsibilitysingle night

    Procedural learning worsens with OSA severity in older adults and is insensitive to short exposure supplemental oxygen therapy

    Sleep medicine

More on Supplemental oxygen therapy

High-intensity interval training

downin humans1

1 study
  1. High-intensity interval training decreases apnea-hypopnea index in humans (obstructive sleep apnea) (Mean difference −37.22 events/h, 95% CI −48.45 to −25.99; low certainty).

    “High-intensity interval training produced the largest reduction in apnea–hypopnea index”

    Reviewobstructive sleep apnea

    Comparative Efficacy of Non-invasive Rehabilitation Therapies for Obstructive Sleep Apnea: A Systematic Review and Network Meta-analysis

    Frontiers in medicine

More on High-intensity interval training

Orforglipron

downin humans1

1 study
  1. Orforglipron decreases apnea-hypopnea index in humans (-13.2 events/h versus placebo (95% CI, -17.7 to -8.7)).

    “in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001)”

    Human trialTrial 1: moderate to severe obstructive sleep apnea and obesity or overweight, not receiving positive airway pressure treatment; compared with placeboOral tabletMaximum tolerated dose equivalent to 9-, 14.5-, or 17.2-mg tablet dose, once daily52 weeks31.4% femalesn = 363

    Orforglipron reduced sleep apnea severity in two trials

    JAMA

More on Orforglipron

Sulthiame

downin humans1−40% reduction

1 study
  1. Sulthiame decreases apnea-hypopnea index in humans (obstructive sleep apnea) (Approximately 40% reduction).

    “Carbonic anhydrase inhibitors (e.g., Sulthiame) stabilise ventilatory instability (Loop Gain), reducing AHI by approximately 40%.”

    Reviewobstructive sleep apnea

    The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine

    Lung India : official organ of Indian Chest Society

More on Sulthiame

Empagliflozin

downin humans1

1 study
  1. Empagliflozin decreases apnea-hypopnea index in humans (Baseline-adjusted between-group difference −11.04 (95% CI −16.72 to −5.35; p < 0.001)).

    “The baseline-adjusted between-group difference in AHI change from baseline to month 3 was −11.04 (95% CI −16.72 to −5.35; p < 0.001).”

    Human trialHeart failure and predominantly obstructive sleep apnea; compared with background therapy alone, before CPAP initiation10 mg daily3 monthsn = 70

    Empagliflozin linked to milder sleep apnea in heart failure

    Antioxidants (Basel, Switzerland)

More on Empagliflozin

Retatrutide

downin humans1

1 study
  1. Retatrutide decreases apnea-hypopnea index in humans (-24.4 events/hour versus placebo (95% CI -34.1 to -14.7)).

    “-24.4 [95% CI, -34.1 to -14.7]”

    Human trialModerate-to-severe obstructive sleep apnea, BMI at least 27, without type 2 diabetes; versus placebo; hybrid-treatment estimand9 mg once weekly80 weeksn = 243

    Retatrutide reduced sleep apnea severity in randomized trials

    The New England journal of medicine

More on Retatrutide

Ballistocardiography device

upin humans1

1 study
  1. Ballistocardiography device increases apnea-hypopnea index in humans (+7.18 events/hour (LoA: -18.09 to + 32.44)).

    “AHI was modestly overestimated by + 7.18 events/hour (LoA: -18.09 to + 32.44).”

    Human trialmalesn = 17

    A pilot validation study of contactless ballistocardiography versus polysomnography for sleep and respiratory assessment in older adults

    Lung India : official organ of Indian Chest Society

More on Ballistocardiography device

Liraglutide

downin humans1

1 study
  1. Liraglutide decreases apnea-hypopnea index in humans (compared with placebo, in people with overweight or obesity and COPD) (-9.87 events/h (β 95% CI -19.5 to -0.247)).

    “Compared to placebo, liraglutide significantly reduced OSA severity”

    Human trialcompared with placebo, in people with overweight or obesity and COPD3.0 mg40 weeks

    Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial

    Clinical obesity

More on Liraglutide

Hypoglossal nerve stimulation

downin humans1

1 study
  1. Hypoglossal nerve stimulation decreases apnea-hypopnea index in humans (obstructive sleep apnea) (-17.6, P < .0001).

    “Significant improvements were observed in apnea-hypopnea index (AHI) (-17.6, P < .0001)”

    Human trialobstructive sleep apnean = 42

    Neurocognitive and Psychosocial Outcomes in Older Adults with Obstructive Sleep Apnea Following Hypoglossal Nerve Stimulation

    Ear, nose, & throat journal

More on Hypoglossal nerve stimulation

Ad libitum feeding

downin humans1

1 study
  1. Ad libitum feeding decreases apnea-hypopnea index in humans (P = 0.03).

    “it decreased significantly from caloric restriction to free feeding (P = 0.03).”

    Human trial2 daysmalesn = 12

    The Sleep/Wake Cycle is Directly Modulated by Changes in Energy Balance

    Sleep

More on Ad libitum feeding

All 21

Effects

6

Cardiovascular mortality

no changein humans2

2 studies
  1. Apnea-hypopnea index was not clearly linked with cardiovascular mortality in humans After full adjustment; association was not statistically significant.

    “However, AHI and HB associations were attenuated and lost statistical significance after full adjustment.”

    HumansAfter full adjustment; association was not statistically significantMedian follow-up of approximately 11 yearsn = 4,904

    Sleep breathing score linked to cardiovascular death

    European journal of preventive cardiology

  2. Apnea-hypopnea index was not clearly linked with cardiovascular mortality in humans (AHI ≥30 events/h using the AHI3%a definition).

    “and in elderly individuals diagnosed using the AHI4% and AHI3% but not the AHI3%a definition.”

    HumansAHI ≥30 events/h using the AHI3%a definitionn = 939

    Impact of different hypopnea definitions on obstructive sleep apnea severity and cardiovascular mortality risk in women and elderly individuals

    Sleep medicine

Reti-CVD age-standardized percentile

no changein humans1

1 study
  1. Apnea-hypopnea index was not clearly linked with Reti-CVD age-standardized percentile in humans (untreated obstructive sleep apnea) (ρ=+0.11, p=0.18).

    “Continuous AHI was not associated with Reti-CVD (ρ=+0.11, p=0.18)”

    Humansuntreated obstructive sleep apnearetina85.6% malesn = 160

    Determinants of Retinal Microvascular Cardiovascular Risk in Obstructive Sleep Apnea: A Phenotype-Based Analysis

    AHA Scientific Sessions 2026 abstract

More on Reti-CVD age-standardized percentile

Chair stand test time

upin humans1

1 study
  1. Apnea-hypopnea index is linked with higher chair stand test time in humans (obstructive sleep apnea) (r = +0.209, p = 0.029).

    “both AHI and ODI correlated modestly with CST time (r = +0.209, p = 0.029 and r = +0.203, p = 0.034, respectively)”

    Humansobstructive sleep apnean = 110

    Sarcopenia and Physical Function in Obstructive Sleep Apnea: A Single-Centre Cross-Sectional Study (The SOSA Study)

    The clinical respiratory journal

Locus coeruleus structural integrity

no changein humans1

1 study
  1. Apnea-hypopnea index was not clearly linked with locus coeruleus structural integrity in this model.

    “other sleep variables such as the apnea-hypopnea index, total sleep time, and sleep efficiency did not contribute significant variance in LC structural integrity in this model”

    Humansin this modellocus coeruleus

    High obstructive sleep apnea hypoxic burden associates with reduced locus coeruleus structural integrity on 7T MRI in older adults

    Sleep

More on Locus coeruleus structural integrity

Cognitive function

downin humans1

1 study
  1. Apnea-hypopnea index is linked with worse cognitive function in humans (β = -0.514; 95% CI: -0.077, -0.031; p < 0.001).

    “Moreover, the apnea-hypopnea index (AHI; β = -0.514; 95% CI: -0.077, -0.031; p < 0.001) negatively affected cognitive e function.”

    Humans

    Does Obstructive sleep apnea mediate the risk of cognitive impairment by expanding the perivascular space?

    Sleep & breathing = Schlaf & Atmung

MMAS-defined moderate to complete erectile dysfunction

no changein humans1OR 1.05

1 study
  1. Apnea-hypopnea index was not clearly linked with MMAS-defined moderate to complete erectile dysfunction in humans (OR 1.05, 95% CI 0.75-1.49; p trend=0.452).

    “but not after further adjustment for body mass index, socioeconomic status and comorbidities (OR 1.05, 95% CI 0.75-1.49, p trend=0.452).”

    HumansSevere sleep disordered breathing versus none; adjusted for age, study site, body mass index, socioeconomic status and comorbiditiesmalesn = 2,676

    Association of Sleep Disordered Breathing with Erectile Dysfunction in Community Dwelling Older Men

    The Journal of urology

More on MMAS-defined moderate to complete erectile dysfunction

Upstream

7

Neighborhood disadvantage

no changein humans1

1 study
  1. Neighborhood disadvantage was not clearly linked with apnea-hypopnea index in adults undergoing PSG or type III sleep testing.

    “greater neighborhood deprivation was associated with more severe sleep-related hypoxia (higher T90 and lower oxygen saturation nadir; p < 0.0001) but not with AHI.”

    Humansin adults undergoing PSG or type III sleep testing

    Neighborhood Disadvantage Association with Sleep Apnea and Longitudinal Cardiovascular Events and Mortality

    Annals of the American Thoracic Society

Male sex

upin humans1

1 study
  1. Male sex is linked with higher apnea-hypopnea index in humans.

    “Men (adults and older adults) remained longer in N1, had a higher number of awakenings, and of apnea-hypopnea index”

    Humansmales

    The influence of sex on sleep characteristics in the adult and older adult population: findings from the EPISONO sleep study

    Frontiers in sleep

Craniofacial asymmetry

no changein humans1

1 study
  1. Craniofacial asymmetry was not clearly linked with apnea-hypopnea index in humans.

    “craniofacial size and asymmetry, an aspect of morphological variation seldom analysed in obstructive sleep apnea research, are both uncorrelated to apnea-hypopnea index.”

    Humans

    Do brachycephaly and nose size predict the severity of obstructive sleep apnea (OSA)? A sample-based geometric morphometric analysis of craniofacial variation in relation to OSA syndrome and the role of confounding factors

    Journal of sleep research

Craniofacial size

no changein humans1

1 study
  1. Craniofacial size was not clearly linked with apnea-hypopnea index in humans.

    “craniofacial size and asymmetry, an aspect of morphological variation seldom analysed in obstructive sleep apnea research, are both uncorrelated to apnea-hypopnea index.”

    Humans

    Do brachycephaly and nose size predict the severity of obstructive sleep apnea (OSA)? A sample-based geometric morphometric analysis of craniofacial variation in relation to OSA syndrome and the role of confounding factors

    Journal of sleep research

Age

downin humans1

1 study
  1. Age is linked with lower apnea-hypopnea index in humans (mild-moderate OSA patients).

    “a significant AHI decrease was noted in mild-moderate patients (P < 0.01)”

    Humansmild-moderate OSA patients7 years

    A 7-year follow-up study of obstructive sleep apnoea in healthy elderly: The PROOF cohort study

    Respirology (Carlton, Vic.)

Neck circumference

upin humans1

1 study
  1. Neck circumference is linked with higher apnea-hypopnea index in humans.

    “Pre-sleep NC and ΔNC correlated directly with AHI and arousal frequency.”

    Humansmalesn = 20

    Relationship of Fluid Accumulation in the Neck to Sleep Structure in Men during Daytime Sleep

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

More on Neck circumference

Strength gains

no changein humans1

1 study
  1. Strength gains showed no clear effect on apnea-hypopnea index in humans.

    “Pearson-r correlation statistic revealed no significant association of mean gains in both arm and leg 1RM strength with change from baseline in AHI (1RM Chest Press, r = 0.15, p = 0.15, and 1RM Leg Press, r = 0.18, p = 0.10).”

    Human trialseven weeks

    Strength training and light physical activity reduces the apnea-hypopnea index in institutionalized older adults

    Journal of the American Medical Directors Association

Associations

35

Cardiovascular mortality

upin humans2HR 1.21

2 studies
  1. Apnea-hypopnea index is associated with cardiovascular mortality in humans (Fully adjusted models) (HR 1.21, 95% CI 0.85–1.72; P=0.128).

    “the independent associations for AHI (HR 1.21; 95% CI 0.85–1.72; P=0.128) and HB (HR 1.25; 95% CI 0.91–1.73; P=0.167) lost statistical significance after full adjustment.”

    HumansFully adjusted modelsMedian follow-up of 11.0 yearsn = 4,904

    New sleep apnea measure is linked to heart death risk

    ESC Congress 2026 abstract

  2. Apnea-hypopnea index is associated with cardiovascular mortality in humans (AHI ≥30 events/h under any of the three hypopnea definitions).

    “AHI ≥30 events/h was associated with increased cardiovascular mortality risk in women, regardless of the hypopnea definition”

    HumansAHI ≥30 events/h under any of the three hypopnea definitionsfemalesn = 1,116

    Impact of different hypopnea definitions on obstructive sleep apnea severity and cardiovascular mortality risk in women and elderly individuals

    Sleep medicine

Hypertension

upin humans2HR 1.015

2 studies
  1. Apnea-hypopnea index is associated with hypertension in humans After WHtR adjustment in KoGES.

    “After WHtR adjustment, hypertension remained associated with AHI in KoGES”

    HumansAfter WHtR adjustment in KoGES

    Comparative cohort analysis of sleep-disordered breathing in German and South Korean populations

    Sleep medicine

  2. Apnea-hypopnea index predicts hypertension in elderly patients with obstructive sleep apnea (HR = 1.015, 95% CI: 1.007-1.023).

    “AHI (HR = 1.015, 95% CI: 1.007-1.023) and Hb level (HR = 1.016, 95% CI: 1.008-1.025) were independent predictors of new-onset hypertension.”

    Humansin elderly patients with obstructive sleep apneamedian 33-monthn = 450

    Factors influencing new-onset hypertension in elderly patients with obstructive sleep apnea: A multicenter cohort study

    Clinical and translational science

More on Hypertension

Mild cognitive impairment

upin humans2OR 1.07

2 studies
  1. Mild cognitive impairment is associated with apnea-hypopnea index in humans (MCI vs controls) (18.7±6.2 vs 5.3±2.0, P<0.01).

    “higher AHI (18.7±6.2 vs 5.3±2.0; P<0.01)”

    HumansMCI vs controlsn = 150

    Comparison of Sleep Architecture in Individuals Aged 65 to 80 Years With and Without Mild Cognitive Impairment Using Multi-Channel Sleep Monitoring

    Medical science monitor : international medical journal of experimental and clinical research

  2. Apnea-hypopnea index is associated with mild cognitive impairment in humans (Non-demented participants; adjusted for age, sex, education, and BMI) (OR 1.07 per unit increase in AHI).

    “for each unit increase in AHI, the odds of being classified as MCI were 7 % higher (OR = 1.07, p = 0.003)”

    HumansNon-demented participants; adjusted for age, sex, education, and BMI70 % femalesn = 115

    "Objective sleep apnea severity, cognitive impairment and AD pathology: Insights from the ALBION cohort"

    Sleep medicine

More on Mild cognitive impairment

Age

downin humans1upin humans1

2 studies
  1. Age is associated with apnea-hypopnea index in humans (perimenopause) (40–46 years: 5±6; 47–52 years: 8±13; 53–58 years: 12±18 events/hour).

    “The total AHI was G1=5±6 events/hour, G2=8±13 events/hour, and G3=12±18 events/hour, with p=0.001.”

    Humansperimenopausefemalesn = 145

    Analysis of Respiratory Variables During Sleep in a Sample of Women in Perimenopause: a retrospective cross-sectional study

    Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)

  2. Age predicts apnea-hypopnea index in humans (obstructive sleep apnea) (β = -1.12, p = 0.024).

    “increasing age was associated with greater reductions in AHI (β = -1.12, p = 0.024).”

    Reviewobstructive sleep apnean = 1,623

    The impact of continuous positive airway pressure combined with lifestyle intervention on patients with obstructive sleep apnea: a multilevel meta-analysis

    Frontiers in medicine

Systolic blood pressure

upin humans1

1 study
  1. Apnea-hypopnea index is associated with systolic blood pressure in humans (Black and Hispanic women; adjusted for age and BMI) (0.47 mmHg higher per 1-event/hour higher AHI; 95% CI 0.09–0.85; p =.017).

    “each 1-event/hour higher AHI was associated with 0.47 mmHg higher systolic BP”

    HumansBlack and Hispanic women; adjusted for age and BMIEach 1-event/hour higher AHIfemalesn = 154

    Polysomnography-Derived Obstructive Sleep Apnea Severity, Wake After Sleep Onset, and Blood Pressure in Black and Hispanic Women of Childbearing Age

    AHA Scientific Sessions 2026 abstract

Cerebral perivascular spaces

upin humans1OR 1.03

1 study
  1. Apnea-hypopnea index is associated with cerebral perivascular spaces in humans (3% higher odds per unit; OR = 1.03, 95% CI 1.01 to 1.04).

    “Each per unit increase in apnea-hypopnea index corresponded to a 3% increase in the odds of PVS”

    Reviewbrainper unit increase in apnea-hypopnea index

    Perivascular space imaging marker and glymphatic function in obstructive sleep apnea: A systematic review and meta-analysis

    Neurobiology of disease

More on Cerebral perivascular spaces

Coronary artery calcium

upin humans1OR 1.06

1 study
  1. Apnea-hypopnea index is associated with coronary artery calcium in humans (statin-free adults; age-sex adjusted) (Adjusted OR 1.06 per event/h; CAC prevalence 11%→27%→53%→100% across severity).

    “apnoea–hypopnoea index (adjusted OR 1.06 per event/h, p = 0.048; CAC prevalence 11%→27%→53%→100% across severity)”

    Humansstatin-free adults; age-sex adjustedper event/h54.5% femalesn = 209

    Three new modifiable correlates of coronary artery calcium beyond age and male sex: uric acid, sleep apnoea severity, and vitamin D from 34-biomarker statin-free phenotyping

    ESC Congress 2026 abstract

More on Coronary artery calcium

Clinical memory scale score

downin humans1

1 study
  1. Apnea-hypopnea index predicts clinical memory scale score in humans (Comorbid insomnia and obstructive sleep apnea) (β=-0.084, 95% CI -0.345 to -0.009).

    “AHI (β=-0.084,95%CI -0.345--0.009; P<0.001) could negatively predict the CMS in COMISA patients.”

    HumansComorbid insomnia and obstructive sleep apnean = 74

    Sleep monitoring and memory impairment in elderly patients with comorbid insomnia and obstructive sleep apnoea

    Chinese Journal of Multiple Organ Diseases in the Elderly

More on Clinical memory scale score

Atrial fibrillation

upin humans1+2% af risk per unit rise in ahi

1 study
  1. Apnea-hypopnea index raises the risk of atrial fibrillation in humans (per unit rise in AHI) (2% increase in AF risk per unit rise in AHI).

    “A dose-response relationship showed a 2% increase in AF risk per unit rise in AHI.”

    Reviewper unit rise in AHI

    Sleep-Disordered Breathing and Sleep Fragmentation in Relation to Atrial Fibrillation Risk: A Systematic Review and Meta-Analysis

    Journal of arrhythmia

More on Atrial fibrillation

Montreal Cognitive Assessment

downin humans1

1 study
  1. Apnea-hypopnea index is associated with Montreal Cognitive Assessment in humans (Patients with obstructive sleep apnea; adjusted correlation) (r=-0.423).

    “total MoCA scores were negatively correlated with AHI and serum irisin levels (r=-0.423, -0.436, both P<0.001)”

    HumansPatients with obstructive sleep apnea; adjusted correlationn = 160

    Relationship between cognitive dysfunction and serum irisin levels in elderly patients with obstructive sleep apnea

    Chinese Journal of Gerontology

More on Montreal Cognitive Assessment

Body weight reduction

downin humans1

1 study
  1. Body weight reduction is associated with apnea-hypopnea index in humans across both SURMOUNT-OSA studies.

    “The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies.”

    Human trialacross both SURMOUNT-OSA studies

    Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight

    Sleep medicine

All 35

Latest

Dec 2025: 10Jan 2026: 14Feb 2026: 16Mar 2026: 12Apr 2026: 2May 2026: 6Jun 2026: 3Jul 2026: 8Aug 2026: 12Sep 2026: 11Oct 2026: 32Nov 2026: 12138 papers in 12 months
Annals of the American Thoracic Society

Sleep apnea deaths showed different patterns by sex and age

Over a median 5.9 years, 10.0% of women and 11.4% of men died, but patterns differed by age and sleep apnea severity.Over a median 5.9 years, 10.0% of women and 11.4% of men died, but patterns differed by age and sleep apnea severity.

Cohort studyPopulations
JAMA

Orforglipron reduced sleep apnea severity in two trials

Over 52 weeks, average hourly breathing disruptions fell by 17.8 with orforglipron versus 4.5 with placebo in one trial, and 17.3 versus 5.3 in the other.Over 52 weeks, average hourly breathing disruptions fell by 17.8 with orforglipron versus 4.5 with placebo in one trial, and 17.3 versus 5.3 in the other.

Randomized trialOrforglipron

See all 322 papers on apnea-hypopnea index